Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Employees - 34100,
CEO - Dr. Christopher S. Boerner Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 117.65B
Altman ZScore(max is 10): 1.55, Piotroski Score(max is 10): 3, Working Capital: $6006000000, Total Assets: $92603000000, Retained Earnings: $14912000000, EBIT: -6432000000, Total Liabilities: $76215000000, Revenue: $48300000000
- Current Price $57.82 - Analyst Target Price $60.68| Ticker | BMY |
| Index | S&P 500 |
| Curent Price | 57.82 |
| Change | -2.99% |
| Market Cap | 117.65B |
| Average Volume | 11.64M |
| Income | -8948.00M |
| Sales | 48.30B |
| Book Value/Share | 8.05 |
| Cash/Share | 5.34 |
| Dividend Est | 2.47 (4.28%) |
| Dividend TTM | 2.42 (4.19%) |
| Dividend Ex-Date | Apr 04, 2025 |
| Employees | 34100 |
| Moving Avg 20days | -3.84% |
| Moving Avg 50days | -1.69% |
| Moving Avg 200days | 8.81% |
| Shares Outstanding | 2.03B |
| Earnings Date | Apr 24 BMO |
| Inst. Ownership | 79.73% |
| Price/Earnings | - |
| Forwad P/E | 9.45 |
| PE Growth | - |
| Price/Sales | 2.44 |
| Price/Book | 7.18 |
| Price/Cash | 10.83 |
| Price/FCF | 8.44 |
| Quick Ratio | 1.15 |
| Current Ratio | 1.25 |
| Debt/Equity | 3.13 |
| Return on Assets | -9.53% |
| Return on Equity | -39.10% |
| Return on Investment | -13.70% |
| Gross Margin | 56.80% |
| Ops Margin | 18.51% |
| Profit Margin | -18.53% |
| RSI | 42.51 |
| BETA(β) | 0.37 |
| From 52week Low | 46.94% |
| From 52week High | -8.70% |
| EPS | -4.43 |
| EPS next Year | 6.12 |
| EPS next Qtr | 1.52 |
| EPS this Year | 485.76% |
| EPS next 5 Year | 73.72% |
| EPS past 5 Year | - |
| Sales past 5 Year | 15.21% |
| EPS Y/Y | -214.24% |
| Sales Y/Y | 7.32% |
| EPS Q/Q | -95.92% |
| Sales Q/Q | 7.54% |
| Sales Surprise | 6.70% |
| EPS Surprise | 14.13% |
| ATR(14) | 1.65 |
| Perf Week | -1.83% |
| Perf Month | -3.34% |
| Perf Quarter | 2.23% |
| Perf Year | 9.63% |
| Perf YTD | 2.23% |
| Target Price | 60.68 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer